BENZOYLNAPELLINE Base (1-O-) | Product ID | L6237 |
| Name | BENZOYLNAPELLINE Base (1-O-) |
| Molecular formula | C29H37NO4 |
| Description |
It is an antiarrhythmic. Diterpenoid Alkaloid , synthesized from Napelline which is extracted from Aconitum karakolicum |
| Biological activity | It has a potent antiarrhythmic activity on a various models of arrhythmia. It is effective for treatment urgent types of arrhythmia. By its antiarrhythmic activity and therapeutic width, 1-O-benzoylnapelline exceeds known antiarrhythmics such as quinidine, procainamide, ajmaline and lydocaine. |
Packaging and Prices
| Packaging | Price (€) | Quantité | Buy Now |
|---|---|---|---|
| 20 mg | 104.00 | ||
| 100 mg | 416.00 | ||
| For quotation of big quantities, please Contact us | |||
Product Technical Documents
![]() | Safety Data Sheet Available on request, please Contact us Ref. SDS_L6237 : unit price : free of charge |
Chemical and Physical Properties
| Product code | L6237 | Molecular weight | 463.60 g/mol |
| Product name | BENZOYLNAPELLINE Base (1-O-) | Physical form | Light yellow crystals |
| CAS No. | 198126-85-1 | Melting point | 112-114 °C |
| RTECS | KW7915000 | Solubility | In butanol Moderate in chloroform and acetone |
| UNIPROT | Optical Activity | Not determined | |
| PubChem SID | |||
| PubChem CID | 3075701 | ||
| Purity | ââ°Â¥ 90 % Method for determining purity: TLC, silica gel KSK system chloroform - methanol 10:1. Mass spectrum | ||
| Toxicity(LD50) | IVN-RAT LD50: 32.0 mg/kg ORL-RAT LD50: 430 mg/kg IPR-RAT LD50: 135 mg/kg |
||
| Chemical Name | 16,17-1alpha-O-Benzoyloxy, 12beta,15beta-dihydroxy, 4beta-methyl, N-ethylnapellane | ||
| Storage & Reconstitution Recommandations |
Store in a cool, dry place |
||
| Savety Recommandations | For research use only — not intended for food, diagnostic or therapeutic use |
||
Bibliographic References
| Product code | L6237 |
| Product name | BENZOYLNAPELLINE Base (1-O-) |
Links
| Product code | L6237 |
| Product name | BENZOYLNAPELLINE Base (1-O-) |
| External Links |
|
|
|
|
|
|
|
|
|
|